Showing results (11-20 of 16) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Pharmacology Research & Perspectives|August 15, 2017
The reversible P2Y12 antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in ratMarkus Rey, Markus Kramberg, Patrick Hess, et al.The Journal of Pharmacology and Experimental Therapeutics|September 11, 2008
Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonistMarc Iglarz, Christoph Binkert, Keith Morrison, et al.Journal of Medicinal Chemistry|May 14, 2004
Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonistsMartin H Bolli, Judith Marfurt, Corinna Grisostomi, et al.Pharmacology Research & Perspectives|December 12, 2017
Cenerimod, a novel selective S1P1 receptor modulator with unique signaling propertiesLuca Piali, Magdalena Birker-Robaczewska, Cyrille Lescop, et al.The Journal of Pharmacology and Experimental Therapeutics|May 18, 2004
Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin SystemMartine Clozel, Christoph Binkert, Magdalena Birker-Robaczewska, et al.The Journal of Pharmacology and Experimental Therapeutics|March 12, 2025
The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosisMagdalena Birker-Robaczewska, Maxime Boucher, Giulia Ranieri, et al.Pageof 2